Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA).

On a global scale, childhood maltreatment is associated with a higher risk for developing some immune-mediated inflammatory disorders.

A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...